ArticleEuropean journal of medical research2026
Association of omega-3 fatty acids with improved prognosis after myocardial infarction: the role of red cell distribution width-an EHR study.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The association between red blood cell distribution width to albumin ratio and migraine: evidence from clinical and population-based cohorts.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundA high red cell distribution width (RDW) reflects an inflammatory state and abnormal red blood cell function, which has been associated with poor prognosis in patients with prior myocardial infarction (MI). Omega-3 fatty acids (n-3 FAs) are inversely related to RDW in the general population but have not been studied in post-MI patients. We aimed to explore associations between n-3 FAs, RDW and prognosis in individuals with prior MI by analyzing electronic health records (EHRs).
methodsThis study analyzed two cohorts from the National Health and Nutrition Examination Survey (NHANES) and the UK Biobank databases. In the NHANES cohort, associations between dietary n-3 FA intake, RDW, and mortality were explored using multivariable Cox proportional hazards regression and restricted cubic splines (RCSs). In the UK Biobank cohort, associations between n-3 blood biomarkers, RDW, and 5 year mortality were examined through Spearman correlations, multivariate Cox proportional hazards regression, RCSs, and Karlson-Holm-Breen (KHB) mediation analysis. Finally, in the internal dataset, this study explored the potential role of RDW in the association between plasma eicosapentaenoic acid (EPA) level and the 6 month major adverse cardiovascular events (MACE) incidence using KHB mediation analysis.
resultsRDW was positively associated with mortality in both cohorts from public databases. Dietary n-3 FA intake were inversely associated with RDW. Blood n-3 biomarkers were significantly inversely associated with RDW and 5 year mortality. Moreover, RDW appears to partially mediate the relationship between n-3 blood biomarkers and 5 year mortality. The internal dataset also suggested that RDW may modestly influence the association between plasma EPA level and 6-month MACE incidence.
conclusionsBoth dietary and blood levels of n-3 FAs are negatively associated with RDW in individuals with prior MI. The findings are consistent with the hypothesis that RDW may play a potential mediating role in the association between n-3 FAs and mortality risk. Given that a high RDW signifies an inflammatory state and abnormal erythrocyte function, the observed association between higher blood levels of n-3 FAs and improved prognosis after MI aligns with potential underlying mechanisms: attenuated inflammation and enhanced erythrocyte function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.